Business·Industry

BioPlus Signs Overseas Distribution Agreement with JD Bio for HA Fillers

JD Bio Expands Overseas Sales Through Global Distribution Network Following Brazil, the company is pushing to expand into markets in Latin America, Europe, and Asia

BioPlus (left) and JD Bio (right) logos (Photo courtesy of BioPlus)

[Edaily Reporter Kim Saemi] #BioPlus announced on the 18th that it has signed an overseas exclusive distribution agreement with JD Bio for its hyaluronic acid (HA) filler product line.

Under this agreement, JD Bio will be responsible for the overseas distribution and sales of BioPlus’s HA filler products. The two companies plan to collaborate to enter new markets and expand their sales networks.

JD Bio is a company that distributes medical aesthetic products such as fillers, botulinum toxin, and skin boosters. It supplies products to approximately 50 countries, including Europe, Southeast Asia, and Central and South America.

J-Bio serves as a global distribution partner for domestic and international medical beauty brands. Recently, it participated as the main sponsor of “AMWC Korea,” an academic conference on aesthetics and anti-aging.

BioPlus develops and manufactures HA filler products based on its proprietary MDM technology for cross-linking hyaluronic acid.

BioPlus is currently working to expand sales of its HA fillers in the Brazilian market. With this agreement, the company plans to expand its distribution channels to markets in Central and South America, as well as Europe and Asia.

Yoon Min-ho, Head of BioPlus, stated, “JD Bio is a partner with global distribution experience and an overseas sales network,” adding, “Through this collaboration, we will diversify our overseas sales base and enhance brand awareness.”

Economy

Corporation

IT·Science

Economy

A Semiconductor Fabless Company Founded by SK Hynix’s Youngest-Ever Executive [VC Cradle]

The biggest bottleneck for AI servers is memory. As the KV cache—where large language models (LLMs) store past computations—accumulates, the required memory capacity increases exponentially. This prob…
2026-07-04 09:00:07

Corporation

Genosco, Tax Risk?… “Lecraza Is ‘Royalty Income’; Its Value Remains Unchanged”

Concerns about “tax risks” have been raised in some quarters of the financial investment, pharmaceutical, and biotech markets regarding Genosco, a subsidiary of OSCOTEC Inc.(039200)specializing in new…
2026-07-04 08:31:02

IT·Science

Celltrion Pharm Inc. Builds a Plant, AriBio Secures Investment… K-Bio in ‘Expansion Mode’ [Weekly Bio Roundup]

As July began (June 29–July 3), the pharmaceutical and biotech industries turned their attention to Celltrion Pharm Inc.’s large-scale investment in production facilities and AriBio’s successful fundr…
2026-07-04 09:01:02